Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans

Neoplasia

Volumn 14, Issue 1, 2012, Pages 1-19

  Soria, Gali ^a   Lebel Haziv, Yaeli ^a   Ehrlich, Marcelo ^a   Meshel, Tsipi ^a   Suez, Adva ^a   Avezov, Edward ^a   Rozenberg, Perri ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; MEMBRANE PROTEIN; PROTEIN TRKN; RANTES; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ARTICLE; BIOTINYLATION; BREAST TUMOR; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSKELETON; ELECTROPORATION; ENDOPLASMIC RETICULUM; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MEMBRANE VESICLE; MICROTUBULE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SULFATION; TRANS GOLGI NETWORK; TUMOR CELL; UBIQUITINATION;

EID: 84856995936     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111122     Document Type: Article

References (68)

1. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
2. Colotta F, Allavena P, Sica A, Garlanda C, and Mantovani A (2009). Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081.
3. Hagemann T, Balkwill F, and Lawrence T (2007). Inflammation and cancer: a double-edged sword. Cancer Cell 12, 300-301.
4. Soria G and Ben-Baruch A (2009). The CCL5/CCR5 Axis in Cancer. Humana Press, New York, NY.
5. Soria G and Ben-Baruch A (2008). The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267, 271-285.
6. Adler EP, Lemken CA, Katchen NS, and Kurt RA (2003). A dual role for tumorderived chemokine RANTES (CCL5). Immunol Lett 90, 187-194.
7. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, and Ben-Baruch A (2002). The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62, 1093-1102.
8. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, and Balkwill FR (2003). A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63, 8360-8365.
9. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, and Peng G (2010). Tumor microenvironments direct the recruitment and expansion of human TH17 cells. J Immunol 184, 1630-1641.
10. Kim JE, Kim HS, Shin YJ, Lee CS, Won C, Lee SA, Lee JW, Kim Y, Kang JS, Ye SK, et al. (2008). LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med 40, 514-522.
11. Cappellen D, Schlange T, Bauer M, Maurer F, and Hynes NE (2007). Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8, 70-76.
12. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, and Pestell RG (2010). c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285, 8218-8226.
13. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, and Weinberg RA (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563.
14. Mira E, Lacalle RA, Gonzalez MA, Gomez-Mouton C, Abad JL, Bernad A, Martinez AC, and Manes S (2001). A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2, 151-156.
15. Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, and Song YH (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 284, 80-85.
16. Prest SJ, Rees RC, Murdoch C, Marshall JF, Cooper PA, Bibby M, Li G, and Ali SA (1999). Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 17, 389-396.
17. Youngs SJ, Ali SA, Taub DD, and Rees RC (1997). Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71, 257-266.
18. Zabouo G, Imbert AM, Jacquemier J, Finetti P,Moreau T, Esterni B, BirnbaumD, Bertucci F, and Chabannon C (2009). CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 11, R1.
19. Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L, and Sun S (2009). Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21, 1113-1121.
20. Forst B, Hansen MT, Klingelhofer J, Moller HD, Nielsen GH, Grum-Schwensen B, Ambartsumian N, Lukanidin E, and Grigorian M (2010). Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS One 5, e10374.
21. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, Jimenez- Baranda S, Garzon A, Lacalle RA, Harshman K, et al. (2003). CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198, 1381-1389.
22. Stormes KA, Lemken CA, Lepre JV, Marinucci MN, and Kurt RA (2005). Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 89, 209-212.
23. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, and Lidereau R (2004). Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10, 6789-6795.
24. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, and Ben-Baruch A (1999). Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59, 4681-4687.
25. Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, and Deissler H (2008). Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 14, 3345-3353.
26. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, and Ben-Baruch A (2006). The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12, 4474-4480.
27. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, and Meshel T (2008). Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44, 191-200.
28. Dupre SA, Redelman D, and Hunter KW Jr (2007). The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 88, 351-360.
29. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, and Abe A (2001). Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7, 285-289.
30. Tedla N, Palladinetti P, Wakefield D, and Lloyd A (1999). Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11, 531-540.
31. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich- Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, et al. (2011). An inflammatory network in breast cancer: coordinated expression of TNFa & IL-1ß with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11, 130-149.
32. Rohl CA, Strauss CE, Misura KM, and Baker D (2004). Protein structure prediction using Rosetta. Methods Enzymol 383, 66-93.
33. Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, Roulin K, Harrenga A, Wells TN, and Proudfoot AE (2004). The x-ray structure of RANTES: heparinderived disaccharides allows the rational design of chemokine inhibitors. Structure 12, 2081-2093.
34. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB III, Snoeyink J, Richardson JS, et al. (2007). MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35, W375-W383.
35. Soria G, Meshel T, and Ben-Baruch A (2009). Chemokines in human breast tumor cells: modifying their expression levels and determining their effects on the malignancy phenotype. Methods Enzymol 460, 3-16.
36. Feniger-Barish R, Yron I, Meshel T, Matityahu E, and Ben-Baruch A (2003). IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 42, 2874-2886.
37. Strous GJ, van Kerkhof P, van Meer G, Rijnboutt S, and Stoorvogel W (1993). Differential effects of brefeldin A on transport of secretory and lysosomal proteins. J Biol Chem 268, 2341-2347.
38. Miller SG, Carnell L, and Moore HH (1992). Post-Golgi membrane traffic: brefeldin A inhibits export from distal Golgi compartments to the cell surface but not recycling. J Cell Biol 118, 267-283.
39. Williams RC Jr, Caplow M, and McIntosh JR (1986). Cytoskeleton. Dynamic microtubule dynamics. Nature 324, 106-107.
40. Coue M, Brenner SL, Spector I, and Korn ED (1987). Inhibition of actin polymerization by latrunculin A. FEBS Lett 213, 316-318.
41. Cingolani LA and Goda Y (2008). Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat Rev Neurosci 9, 344-356.
42. El Golli N, Issertial O, Rosa JP, and Briquet-Laugier V (2005). Evidence for a granule targeting sequence within platelet factor 4. J Biol Chem 280, 30329-30335.
43. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C, Trkola A, Marchant D, Clapham PR, and Wells TN (2001). The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 276, 10620-10626.
44. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, and Vita C (2001). Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40, 6303-6318.
45. Boelens J, Lust S, Offner F, Bracke ME, and Vanhoecke BW (2007). Review. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 21, 215-226.
46. Ellgaard L, Molinari M, and Helenius A (1999). Setting the standards: quality control in the secretory pathway. Science 286, 1882-1888.
47. Tsai YC and Weissman AM (2010). The unfolded protein response, degradation from endoplasmic reticulum and cancer. Genes Cancer 1, 764-778.
48. MacDermott RP, Schmidt RE, Caulfield JP, Hein A, Bartley GT, Ritz J, Schlossman SF, Austen KF, and Stevens RL (1985). Proteoglycans in cellmediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med 162, 1771-1787.
49. Stevens RL, Otsu K, Weis JH, Tantravahi RV, Austen KF, Henkart PA, Galli MC, and Reynolds CW (1987). Co-sedimentation of chondroitin sulfate A glycosaminoglycans and proteoglycans with the cytolytic secretory granules of rat large granular lymphocyte (LGL) tumor cells, and identification of a mRNA in normal and transformed LGL that encodes proteoglycans. J Immunol 139, 863-868.
50. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, and Luster AD (1998). ß-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391, 908-911.
51. Handel TM, Johnson Z, Crown SE, Lau EK, and Proudfoot AE (2005). Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem 74, 385-410.
52. Esko JD, Stewart TE, and Taylor WH (1985). Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA 82, 3197-3201.
53. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I, and Ilan N (2004). Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 279, 44084-44092.
54. Rabenstein DL (2002). Heparin and heparan sulfate: structure and function. Nat Prod Rep 19, 312-331.
55. Zcharia E, Metzger S, Chajek-Shaul T, Friedmann Y, Pappo O, Aviv A, Elkin M, Pecker I, Peretz T, and Vlodavsky I (2001). Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia 6, 311-322.
56. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, andWells TN (1999). Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38, 12959-12968.
57. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, Zamir E, Geiger B, Vlodavsky I, and Katz BZ (2002). Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 281, 50-62.
58. Sweeney MD, Yu Y, and Leary JA (2006). Effects of sulfate position on heparin octasaccharide binding to CCL2 examined by tandem mass spectrometry. J Am Soc Mass Spectrom 17, 1114-1119.
59. Meissen JK, Sweeney MD, Girardi M, Lawrence R, Esko JD, and Leary JA (2009). Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif. J Am Soc Mass Spectrom 20, 652-657.
60. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, and Wells TN (1997). Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36, 13570-13578.
61. Farley JR, Nakayama G, Cryns D, and Segel IH (1978). Adenosine triphosphate sulfurylase from Penicillium chrysogenum equilibrium binding, substrate hydrolysis, and isotope exchange studies. Arch Biochem Biophys 185, 376-390.
62. Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG, Bikfalvi A, and Prats H (2010). Functional divergence between 2 chemokines is conferred by single amino acid change. Blood 116, 4703-4711.
63. Culley FJ, Fadlon EJ, Kirchem A, Williams TJ, Jose PJ, and Pease JE (2003). Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur J Immunol 33, 1302-1310.
64. Hol J, Kuchler AM, Johansen FE, Dalhus B, Haraldsen G, and Oynebraten I (2009). Molecular requirements for sorting of the chemokine IL-8/CXCL8 to endothelial Weibel-Palade bodies. J Biol Chem 284, 23532-23539.
65. Meen AJ, Oynebraten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, and Kolset SO (2011). Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROa/ CXCL1. J Biol Chem 286, 2636-2647.
66. Zehe C, Engling A, Wegehingel S, Schafer T, and Nickel W (2006). Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc Natl Acad Sci USA 103, 15479-15484.
67. Devalaraja MN and Richmond A (1999). Multiple chemotactic factors: fine control or redundancy? Trends Pharmacol Sci 20, 151-156.
68. Mantovani A (1999). The chemokine system: redundancy for robust outputs. Immunol Today 20, 254-257.